Proteina프로티나

Proteina remains deeply loss-making, with its share price well below its 52-week high despite a sharp rise over three months.

Proteina is a Korean protein-protein interaction data and drug discovery company that listed on KOSDAQ in July 2025. Trailing twelve-month revenue to H1 2026 was about ₩1.4B against an operating loss of about ₩16.1B, and free cash flow was about -₩11.9B. Its market capitalisation is about ₩572B, with the shares at ₩51,500, down 4.1% over one month and 3.7% over one year but up 213.8% over three months.

What stands out

• Trailing revenue is about ₩1.4B while operating loss is about ₩16.1B, an operating margin of roughly -1113%.
• Cash is about ₩2.1B and the filings show no borrowings, with liabilities at 16.6% of equity.
• Price-to-book is about 25 times and price-to-sales about 396 times; P/E is not meaningful because earnings are negative.
• The data's DCF model gives a base fair value of ₩932 per share, which is far below the current ₩51,500 price; this is a model output, not a forecast.
• Foreign ownership fell from 5.2% to 1.1% over 60 days, and 20-day flows were net negative for foreign and retail investors but positive for institutions.

What to watch

• The next results release and whether losses narrow relative to the roughly ₩1.4B trailing revenue base.
• Progress of the osteoarthritis drug technology transfer talks with Japanese pharmaceutical companies, which the news reports describe as due diligence stage; the data does not confirm any deal terms.
• Insider shareholding and 5%+ holding reports from August 2026, and the stock purchase option grant announced in July 2026.